Trump Orders Psychedelics Research

President Donald Trump signed an executive order on April 18 directing federal agencies to speed research and review of psychedelic drugs for serious mental illness. (whitehouse.gov) The order tells the Food and Drug Administration and the Department of Health and Human Services to work with the Department of Veterans Affairs on psychedelic treatments, with veterans named as a priority group. It specifically points to drugs including psilocybin and ibogaine. (whitehouse.gov) Trump also directed $50 million in federal funding toward making the treatments more accessible and told the Food and Drug Administration to fast-track reviews for qualifying psychedelic drugs. The White House fact sheet says the policy is aimed at patients with “serious mental illness” and “treatment-resistant” conditions. (whitehouse.gov) Psychedelics are drugs that alter perception, mood, and consciousness. In medicine, researchers are testing whether supervised doses paired with therapy can reduce symptoms of post-traumatic stress disorder, depression, addiction, and anxiety. (apnews.com) Ibogaine has become central to this debate because some veterans have traveled abroad for treatment, even though the drug remains illegal in the United States under the federal government’s most restrictive drug category. Reuters and The Associated Press both reported that veterans and advocates have pushed Washington to move faster. (apnews.com) (usnews.com) The White House said more than 14 million American adults have a serious mental illness, and the order frames psychedelics as one response to high suicide rates and hard-to-treat psychiatric conditions. National Public Radio stations reporting on the signing said Trump highlighted post-traumatic stress disorder among active-duty troops and veterans. (whitehouse.gov) (wunc.org) The order does not legalize psychedelics for general use. It pushes federal agencies to remove research barriers, expand trials, and speed regulatory decisions for drugs that already meet the government’s review standards. (whitehouse.gov) That matters because psychedelic research has been growing for years, but federal law and drug scheduling have limited how quickly studies could move. Euronews reported that the new order is being read as a signal of federal support for more clinical trials. (euronews.com) Supporters say the policy could expand options for patients who have not improved with standard antidepressants or talk therapy. Critics and some medical experts have warned that ibogaine in particular carries serious safety risks, including heart complications, and still needs more rigorous study before wider use. (cnbc.com) (apnews.com) What happens next is more procedural than immediate: agencies now have to decide how to carry out the order, which drugs qualify for faster review, and how quickly new trials can start. For now, the clearest change is that the White House has put psychedelic medicine inside the federal mental-health agenda. (whitehouse.gov)